Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

UNIST researcher named as recipient of Merck’s 2018 Life Science Awards

Jun Ho Lee, a doctroral student in Life Sciences at UNIST, has been named as a recipient of Merck's 2018 Life Science Awards in Tumor Biology, receiving the grand prize of $10,000.

21 Jan 2019

Researchers identify new therapeutic target in the fight against chronic liver diseases

Chronic liver disease is known as the silent killer, as it shows no obvious symptoms until the disease has progressed to an advanced stage. Therefore, making a proper diagnosis in the early stage of disease progression can be a clinical challenge.

18 Jan 2019

Research suggests possible way to improve survival in African-Americans undergoing liver transplant

Among African-American adults undergoing liver transplant to treat liver cancer, patients whose organ donor was also African-American lived significantly longer than those with a racially unmatched donor, report authors of a new study using national data.

10 Jan 2019

Researchers synthesize new compound that inhibits replication of hepatitis C virus

A new compound that inhibits the replication of hepatitis C virus in several stages of its lifecycle - and is also capable of acting on bacteria, fungi and cancer cells - has been synthesized by researchers at São Paulo State University in Brazil.

19 Dec 2018

New approach turns B cells into factories that secrete sacs containing microRNAs

Cancer immunotherapy -- efforts to better arm a patient's own immune system to attack tumors -- has shown great potential for treating some cancers. Yet immunotherapy doesn't work for everyone, and some types of treatment can cause serious side effects.

5 Dec 2018

Merck declares 2018 Life Science Award winners

Merck, the vibrant science and technology company, recognized three graduate students who have demonstrated innovation in life science at an awards ceremony at the company’s global headquarters in Darmstadt, Germany recently.

From Merck 20 Nov 2018

Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma

Hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma (HCC) and was estimated to be responsible for 745,000 deaths in 2012.

13 Nov 2018

Circadian clock could play key role in the fight against liver cancer

The body's internal clock could play a critical role in the fight against certain types of liver cancer, according to a preclinical study by scientists from The University of Texas Health Science Center at Houston (UTHealth). The results were published recently in the journal Nature Communications.

8 Nov 2018

Study offers hope of early detection, treatment of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure -- but now a study offers hope of early detection, and targets for new treatments.

31 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack.

17 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

UK and European research collaborations receive vote of confidence by three major cancer charities

UK and European research collaborations in cancer research have received a vote of confidence by three major cancer charities, with an announcement today of approximately £30 million into six international projects.

20 Sep 2018

Cellular environment affects type of tumor development

Liver cancer is the second leading cause of cancer death worldwide. Two different forms of primary liver cancer cover the majority of cases: About 10 to 20 percent of those affected develop a bile duct carcinoma within the liver (intrahepatic cholangiocellular carcinoma; ICC), the far higher proportion of liver cancers are hepatocellular carcinomas.

12 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Novel approaches for personalized risk prognosis and individualized treatment of NAFLD

More and more adults - but also about 34 percent of obese children - suffer from non-alcoholic fatty liver disease. An unhealthy lifestyle with little physical activity and a diet high in fat, sugar and fructose and/or a genetic predisposition can be the underlying caus.

31 Aug 2018

Researchers discover mechanism that steers growth of cancer cells in melanoma and liver cancer

Melanoma and liver cancer are becoming more widespread in Europe and the US. Whilst both diseases progress very differently, they are among the types of cancer which are most likely to be fatal in the Western world.

29 Aug 2018

Study suggests new strategies for using cell metabolism to treat cancer

Researchers at the University of Cincinnati College of Medicine have discovered that cell metabolism plays an important role in the ability of cells to start a survival program called autophagy, an unwanted side effect of some anti-cancer drugs that helps some tumor cells dodge treatment and eventually regrow into new tumors.